

Lymphatic Compression

Compression is the cornerstone of lymphedema treatment across all guidelines. The mechanism involves reducing capillary ultrafiltration, preventing lymph backflow into the interstitial space, and augmenting the "muscle pump" effect during activity. Key outcomes:

- A prospective study of 232 extremities treated with pneumatic compression therapy showed a **28% decrease in absolute limb volume** ($p < 0.001$), significant improvement in SF-36 quality of life across 7 of 8 domains ($p < 0.001$), and improved leg lymphedema complexity scores at 1 year.
- In breast cancer-related lymphedema (BCRL), a meta-analysis of 14 RCTs ($n = 1,397$) found IPC **reduced lymphedema incidence by 64%** after surgery (RR 0.36, 95% CI 0.22–0.58) and improved limb extension function. Optimal parameters were **≤ 40 mmHg pressure and > 2 weeks of treatment**.
- A study of 196 lower extremity lymphedema patients treated with advanced pneumatic compression devices (APCDs) demonstrated consistent volume reductions, with **35% achieving $> 10\%$ limb volume reduction**, along with improved skin fibrosis and physical function.
- The APTA Academy of Oncologic Physical Therapy guideline recommends compression garments and bandaging as **Grade A interventions** for all stages of BCRL, with IPC considered for Phase II home care (Grade C).

Cellulitis Prevention — A Landmark Finding

An NEJM RCT (PATCH trial) provides the most compelling evidence for compression in cellulitis prevention. In 84 patients with chronic leg edema and recurrent cellulitis, compression therapy reduced cellulitis recurrence from **40% to 15%** (HR 0.23, 95% CI 0.09–0.59; $p = 0.002$) — the trial was stopped early for efficacy. At 12 months, the compression group had a **4.3% decrease in leg volume** while the control group had a 1.3% increase (between-group difference: –5.7 percentage points).

This is particularly significant because the study population had risk factors predictive of antibiotic prophylaxis failure (preexisting edema, BMI ≥ 33 , multiple

prior episodes), suggesting compression addresses a gap that antibiotics alone cannot fill.

Insurance database analyses further showed that APCD initiation was associated with **significant reductions in cellulitis episodes, outpatient visits, manual therapy requirements, and overall healthcare costs** — saving over **\$3,200 per patient per year** through reduced hospitalizations for lymphedema-associated complications.

****Key Caveats:** Compression is **contraindicated** in patients with significant peripheral artery disease (ABI < 0.5), and caution is warranted with ABI 0.5–0.8 (modified compression with inelastic wraps). An ankle-brachial index should be performed before initiating compression in at-risk patients.

References

Davies, C., Levenhagen, K., Ryans, K., Perdomo, M., & Gilchrist, L. (2020). Interventions for breast cancer-Related Lymphedema: Clinical Practice Guideline From the Academy of Oncologic Physical Therapy of APTA. *Physical therapy*, 100(7), 1163–1179. <https://doi.org/10.1093/ptj/pzaa087>

Desai, S. S., Shao, M., & Vascular Outcomes Collaborative (2020). Superior Clinical, Quality of Life, Functional, and Health Economic Outcomes with Pneumatic Compression Therapy for Lymphedema. *Annals of vascular surgery*, 63, 298–306. <https://doi.org/10.1016/j.avsg.2019.08.091>

Ezzo, J., Manheimer, E., McNeely, M.L., et al. (2026) Manual lymphatic drainage for lymphedema following breast cancer treatment. *Cochrane Database of Systematic Reviews 2015*, Article number CD003475. DOI:10.1002/14651858.

Fukaya, E. & Kolluri, R. (2024). Nonsurgical management of chronic venous insufficiency. *The New England Journal of Medicine*, 391(24), 2350-2359. DOI: 10.1056/nejmCP2310224

Lurie, F., Malgor, R. D., Carman, T., Dean, S. M., lafrati, M. D., Khilnani, N. M., Labropoulos, N., Maldonado, T. S., Mortimer, P., O'Donnell, T. F., Jr, Raffetto, J. D., Rockson, S. G., & Gasparis, A. P. (2022). The American Venous Forum, American Vein and Lymphatic Society and the Society for Vascular Medicine expert opinion

consensus on lymphedema diagnosis and treatment. *Phlebology*, 37(4), 252–266.
<https://doi.org/10.1177/02683555211053532>

**Patel, H., Skok, C., & DeMarco, A. (2022). Peripheral edema: Evaluation and management in primary care. *American Family Physician*, 106(5), 557-564. Retrieved from <https://www.aafp.org/afp/2022/1100/peripheral-edema>

Rockson S. G. (2008). Diagnosis and management of lymphatic vascular disease. *Journal of the American College of Cardiology*, 52(10), 799–806.
<https://doi.org/10.1016/j.jacc.2008.06.005>

Singer, A.J., Tassiopoulos, A., & Kirsten, R.S. (2017). Evaluation and management of lower-extremity ulcers. *The New England Journal of Medicine*, 377(16), 1559-1567.
DOI: 10.1056/NEJMr1615243

Su, L., Huang, H., Tong, Y., Dong, L., Gu, C., Zhuang, S., Bai, S., & Jin, Y. (2025). Intermittent pneumatic compression devices for the prevention and treatment of breast cancer-related lymphedema-a systematic review and meta-analysis. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*, 33(12), 1113. <https://doi.org/10.1007/s00520-025-10159-8>

Webb, E., Newman, T., Bowden, F.J., et al. (2020). Compression therapy to prevent recurrent cellulitis of the leg. *The New England Journal of Medicine*, 383(7), 630-639.
DOI: 10.1056/NEJMoa1917197